The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Pirtobrutinib, venetoclax, and rituximab in the treatment of R/R CLL: insights from the BRUIN trial
Catherine Coombs, MD, UC Irvine Health, Orange, CA, comments on an extension of the BRUIN trial (NCT03740529), which has found promising efficacy of pirtobrutinib combined with venetoclax ± rituximab in the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). This has led to the development of the Phase III BRUIN CLL-322 trial (NCT04965493), comparing pirtobrutinib plus venetoclax and rituximab to venetoclax and rituximab. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
